OrthoPediatrics Corp. (NASDAQ:KIDS – Get Free Report) General Counsel Daniel Gerritzen sold 8,614 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $17.25, for a total transaction of $148,591.50. Following the completion of the sale, the general counsel directly owned 149,533 shares of the company’s stock, valued at $2,579,444.25. The trade was a 5.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
OrthoPediatrics Stock Performance
Shares of KIDS stock opened at $16.66 on Thursday. The firm has a market cap of $421.16 million, a price-to-earnings ratio of -9.86 and a beta of 1.07. The company’s 50 day moving average is $17.67 and its 200 day moving average is $17.93. The company has a quick ratio of 2.65, a current ratio of 5.55 and a debt-to-equity ratio of 0.28. OrthoPediatrics Corp. has a 52-week low of $15.28 and a 52-week high of $26.40.
OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.11. The company had revenue of $61.61 million during the quarter, compared to analyst estimates of $61.27 million. OrthoPediatrics had a negative return on equity of 6.70% and a negative net margin of 16.77%. On average, sell-side analysts anticipate that OrthoPediatrics Corp. will post -0.93 EPS for the current fiscal year.
Institutional Trading of OrthoPediatrics
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on KIDS shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Thursday, January 22nd. Truist Financial boosted their target price on shares of OrthoPediatrics from $19.00 to $20.00 and gave the stock a “hold” rating in a report on Monday, March 2nd. BTIG Research increased their price target on shares of OrthoPediatrics from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Needham & Company LLC raised their price target on shares of OrthoPediatrics from $26.00 to $30.00 and gave the company a “buy” rating in a report on Friday, February 27th. Finally, Wall Street Zen raised shares of OrthoPediatrics from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $24.67.
Read Our Latest Stock Report on KIDS
Trending Headlines about OrthoPediatrics
Here are the key news stories impacting OrthoPediatrics this week:
- Negative Sentiment: CEO David R. Bailey sold 19,535 shares (~$336,979), reducing his direct stake by ~6.15%. SEC Filing
- Negative Sentiment: CFO Fred Hite sold 12,993 shares (~$224,129), trimming his holding by ~4.47%. SEC Filing
- Negative Sentiment: General Counsel Daniel J. Gerritzen sold 8,614 shares (~$148,592), cutting his stake by ~5.45%. SEC Filing
- Negative Sentiment: Insider Gregory A. Odle sold 8,433 shares (~$145,469), reducing his position by ~4.30%. SEC Filing
- Negative Sentiment: Insider Joseph W. Hauser sold 8,596 shares (~$148,281), decreasing his stake by ~4.23%. SEC Filing
About OrthoPediatrics
OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.
The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.
See Also
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.
